News
-
16 May 2019
Immunocore to Present New Tebentafusp (IMCgp100) Data in Advanced Melanoma at Upcoming 2019 ASCO Annual Meeting -
13 May 2019
Immunocore Launches Campaign to Educate Physicians on Rare Eye Cancer -
7 May 2019
Immunocore appoints Dr Mohammed Dar as Head of Clinical Development and Chief Medical Officer -
3 April 2019
Immunocore’s Lead Asset Tebentafusp Gains Fast Track Designation for Metastatic Uveal Melanoma -
15 January 2019
Immunocore names David Berman as Head of R&D -
4 January 2019
Immunocore appoints Bahija Jallal as Chief Executive Officer -
19 November 2018
Immunocore to co-develop IMC-C103C, a T cell redirecting bi-specific biologic, with Genentech -
26 October 2018
Immunocore CEO Andrew Hotchkiss appointed to the Board of the BIA -
5 September 2018
Immunocore strengthens IP position in the field of TCR-based therapeutics -
20 August 2018
Immunocore Announces Start of Phase I ImmTAC® Study in Patients with Solid Tumours